NEW YORK (GenomeWeb) – Blood-based cancer testing firm CellMax Life officially launched today having raised $9 million in series A-1 venture financing, which — combined with earlier investments — brings its total funds raised to date to $14 million.

The $9 million funding round was led by Silicon Valley venture capital firm Artiman, as well as several Taiwanese venture investors including Acer Founder and Chairman Stan Shih, CellMax said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.